BeOne Medicines Ltd. American Depositary Shares (ONC)

Amgen has declared a quarterly dividend of $2.38 per share, to be paid on December 12, 2025, to stockholders of record as of November 21, 2025.

Zymeworks, a clinical-stage biotechnology company, announced participation in upcoming investor conferences and highlighted its progress in developing biotherapeutics for cancer and other diseases, including the FDA-approved zanidatamab for biliary tract cancer.

Summit Therapeutics' lung cancer drug ivonescimab showed statistically significant improvement in progression-free survival in a phase III trial, outperforming the current standard of care. This positive trial result has sent the company's stock price soaring.